Mangafodipir trisodium injection (MnDPDP) is an intravenously administered manganese chelate undergoing clinical evaluation for magnetic resonance imaging contrast enhancement of the hepatobiliary system. The anticipated single clinical dose for adults is 5 /xmol/kg body wt. MnDPDP, as well as the inorganic salt, MnCl 2 , was previously shown to induce a specific syndrome of skeletal abnormalities in rats. The syndrome malformations included angulated or irregularly shaped clavicle, femur, fibula, humerus, ilium, radius, scapula, tibia, and7or ulna. The objective of the present study was to assess the developmental toxicity of MnDPDP in a second mammalian species, the New Zealand White rabbit. MnDPDP was intravenously administered daily to groups of rabbits (22 per group) on Days 6 through 18 of pregnancy at doses of 0 (saline), 5, 20, 40, and 60 ^mol/kg MnDPDP. Fetuses were examined on Day 29 of pregnancy for external, visceral, and skeletal abnormalities. Treatment with MnDPDP did not result in overt symptoms of maternal toxicity, and there were no significant effects on maternal body weight gains or feed consumption. The maternal no-observed-adverse-effect level (NOAEL), therefore, was 60 /jmol/kg MnDPDP. Treatment with MnDPDP resulted in a significant increase in postimplantation loss at 60 /xmol/kg, but there was no significant increase in external, visceral, or skeletal abnormalities at any dose. The developmental NOAEL for MnDPDP, therefore, was 40 //mol/kg. These results indicate that the developmental toxicity profile of MnDPDP differs considerably in the rat and rabbit. In the rat, this compound induces specific skeletal abnormalities, whereas in the rabbit, embryo/fetal toxicity is the most sensitive developmental endpoint with no evidence for the induction of specific skeletal abnormalities, o 19% soday of ganese being developed for enhancement of the hepatobiliary system during magnetic resonance imaging (MRI) procedures (Hamm et a/., 1992) . The anticipated single clinical intravenous dose of MnDPDP for adult patients is 5 //mol/kg body wt.
Previous nonclinical studies have demonstrated MnDPDP to have low acute toxicity in rodents (minimum lethal dose > 2000 /xmol/kg in mice and rats), liver and kidney toxicity when administered repeatedly to rats and cynomolgus monkeys at a daily dose of 289 ^zmol/kg [no-observed-adverseeffect levels (NOAELs) of 116 ^mol/kg for rats and 29 /Ltmol/kg for monkeys], no significant hemodynamic effects in anesthetized dogs at single intravenous doses up to 232 ptmol/kg, and no effects on male or female fertility in rats (NOAEL for male fertility, 100 //mol/kg; NOAEL for female fertility, 30 //mol/kg) (Elizondo et ai, 1991; Grant et ai, 1994a) .
Intravenous administration of MnDPDP to inseminated rats on Days 6 through 17 of pregnancy, however, resulted in the induction of a specific syndrome of fetal skeletal malformations (Grant and Ege, 1995; Treinen et ai, 1995) . The syndrome malformations included angulated or irregularly shaped clavicle, femur, fibula, humerus, ilium, radius, scapula, tibia, and/or ulna. The NOAEL for these skeletal malformations in rats was 5 /zmolAg when administered intravenously on Days 6 through 17 of pregnancy. Further studies demonstrated that manganese is the teratogenic component of MnDPDP since intravenously administered MnCl 2 resulted in the same skeletal malformations in rats as MnDPDP, and the ligand (dipyridoxal diphosphate, DPDP) was without developmental effects in this species (Grant and Ege, 1995; Treinen et ai, 1995) .
The present investigation was undertaken to assess the developmental toxicity of MnDPDP in a second mammalian species, the New Zealand White rabbit.
MATERIALS AND METHODS
Test and control materials. Mangafodipir trisodium was synthesized and formulated for parenteral administration by Nycomed Inc., Collegeville,
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BLAZAK ET AL. Pennsylvania, and contained 50 mM mangafodipir trisodium (manganese dipyridoxal diphosphate, MnDPDP, Fig. I ) The chemical purity of MnDPDP was greater than 99%. The terminally sterilized (autoclave) 50 mM formulation was chemically and physically stable when stored at room temperature, and had an osmolahty of 312 mOsm. Dose volumes of the 50 mM formulation administered to the animals were adjusted to achieve the desired dosage. Sodium Chloride Injection USP, 0 9%, was used as the control material.
Animals. New Zealand White rabbits were obtained from Hazleton Research Products, Inc., Kalamazoo, Michigan. The females were superovulated with 50 USP units of human chorionic gonadotropin (hCG) 3 weeks before insemination. Semen was collected from proven donors of the same strain using, an artificial vagina. Each female was artificially inseminated with a minimum of 0.5 X 10 6 sperm. Ovulation was induced with an intravenous injection of 100 USP units of hCG within approximately 0 5 hr of insemination. The day of insemination was designated as Day 0 of pregnancy. Inseminated rabbits were randomly assigned to treatment groups prior to the first administration of test or control material.
Rabbits were individually caged in temperature-controlled (mean, 68.1°F; range, 67-70°F) and humidity-controlled (mean, 56%; range, 54-60%) rooms with a 12-hr light/I 2-hr dark cycle. Municipal water was available to the animals ad libitum, and the animals were provided with 125 g/day Certified Rabbit Chow (Purina Mills, Inc., St. Louis, MO). Female rabbits were approximately 8 months old at insemination and weighed 3.1 to 4 3 kg. Dosages and treatment regimen. MnDPDP was administered intravenously, via the marginal ear vein, to groups of inseminated rabbits (22 per group) at dosages of 5, 20, 40, and 60 //moL/kg body wt/day on Days 6 through 18 of pregnancy. Dosages were selected based on previous toxicity studies in this species, and knowledge of the developmental toxicity of this test article in the rat (Treinen et ai. 1995) . Animals in the control group were administered 0.9% sodium chloride according to the same treatment regimen. Intravenous injections were administered at the rate of approximately I ml/min Maternal parameters. Female rabbits were observed daily for changes in appearance, behavior, mortality, and evidence of abortion. The females were weighed at various times throughout the study and consumption of feed was recorded. On Day 29 of pregnancy, all surviving females were euthanized by an intravenous injection of sodium pentobarbital and necropsied. The uterus was excised, and the numbers and positions of viable and nonviable fetuses and early and late resorptions and the total numbers of implantations and corpora lutea were determined. Uteri from females that appeared nonpregnant were placed in 10% ammonium sulfide to facilitate detection of implantations. A macroscopic necropsy on all major organs was also performed for each female.
Fetal parameters.
Viable fetuses were weighed and euthanized with an intraperitoneal injection of sodium pentobarbital. Fetuses were then examined for external, macroscopic abnormalities including examination of the palate. Fetuses were dissected, examined for internal visceral abnormalities, and sexed by examination of the reproductive tract. Following internal examination, all fetuses were eviscerated and stained with Alizarin Red S (Dawson, 1926) for skeletal examination Statistical analysis. Analysis of variance techniques were used in the analysis of maternal and fetal body weights, maternal feed consumption, and numbers of corpora lutea, implantations, male and female fetuses, preand postimplantation losses, and resorptions. When a significant (i.e., p « 0.05) treatment effect occurred, a Dunnett's /-test study was used to compare the treated groups with the control group. Maternal, litter count, and proportion data were analyzed with the Kruskal-WaJlis test followed by the Mann-Whitney U test. Indicator variables, such as fetal external, visceral, and skeletal observations and litter incidences of such, were analyzed using the chi-square test followed with Fisher's exact test. Throughout this study, whenever significant differences are discussed, statistical significance is implied (p < 0.05)
RESULTS
Intravenous administration of MnDPDP to inseminated female rabbits did not result in overt maternal toxicity. There were no clinical signs of toxicity attributable to treatment, no effects on behavior, no maternal observations at necropsy believed to be related to administration of MnDPDP, and no effects on maternal body weight gain or feed consumption. Three animals aborted during the study, one each in the control and 5 and 20 //mol/kg groups. These abortions were considered unrelated to administration of MnDPDP since there was no dose response and one abortion occurred in a control female.
A number of reproductive parameters were adversely affected in animals administered MnDPDP (Table 1) . Postimplantation loss was significantly increased for females administered 60 //mol/kg MnDPDP. The degree of postimplantation loss is perhaps best appreciated by examining the actual numbers of conceptuses lost, which were 18 for the control group and 5, 15, 28, and 55 for the 5, 20, 40, and 60 //mol/kg MnDPDP groups, respectively. Although not statistically significant, an increase in the number of pregnant females with no viable fetuses and a decrease in the mean number of viable fetuses per female for the 60 ^zmol/kg group are consistent with developmental toxicity. Mean fetal weight was also reduced by approximately 10% in the 60 //mol/kg/day group, but this difference was not significantly different from the control value.
Intravenous administration of MnDPDP to inseminated rabbits did not result in a significant increase in external, visceral, or skeletal malformations in offspring (Tables 2-4) . Neither the fetal nor litter incidence of malformations was significantly different from control. There were no significant effects of treatment with MnDPDP on developmental variations or ossification in viable fetuses.
DISCUSSION
Overt maternal toxicity in response to treatment with MnDPDP was not observed in this study at daily intravenous doses up to 60 //mol/kg. The NOAEL, therefore, for maternal toxicity in this species is at least 60 /zmol/kg/day when administered on Days 6 through 18 of pregnancy.
Developmental toxicity of MnDPDP, as evidenced by a statistically significant increase in postimplantation loss, occurred in females exposed to 60 ^xmol/kg/day. Similar effects on postimplantation loss have been described in mice after subcutaneous administration of MnCl 2 (Sanchez et al., 1993) or after intraperitoneal administration of MnSO 4 (Webster and Valois, 1987) . This effect either could be a direct toxic effect on the embryo/fetus or could be maternally mediated in that maternal tissues (e.g., uterus) were affected which then affected the growth and development of the offspring. Although some marginal effects on the number of viable fetuses and postimplantation loss were observed in the 40 mol/kg MnDPDP group as compared with the saline control group, these effects were not statistically significant and are within published historical control ranges for this species and strain (Lang, 1993) . MnDPDP did not significantly increase external, visceral, or skeletal fetal malformations us- * Fused costal cartilage and fused stemebrae. c Includes various combinations of the following-fused centra, absent centra, fused arches, small arches, extra arches, misaligned vertebrae, rib fusion, rib missing, articulating head absent, rib ossification interruption, extra rib, absent rib, forked nb, and malpositioned rib.
d Includes various combinations of the following: small centra, absent arches, large arches, extra arches, fused arches, and misaligned vertebrae.
' Includes small (unilateral or bilateral) or absent (unilateral) Tl rib. 1 Includes one or more of the following: small vertebrae, vertebrae close together, fused vertebrae, and misaligned vertebrae.
ing a dose high enough to result in increased postimplantation loss. MnDPDP, therefore, is not teratogenic in this species. The most prevalent malformations observed in this study, fused sternebrae and vertebral and rib malformations, were observed in both saline control and MnDPDP-exposed animals and are relatively common malformations in this species and strain (Lang, 1993) . In addition, the fetal and litter incidences for all malformations observed within this study are within the historical control ranges for this species and strain in this laboratory. The NOAEL for developmental toxicity of MnDPDP in this species, therefore, is 40 fj,mo\/ kg/day when administered intravenously on Days 6 through 18 of pregnancy.
MnDPDP has a very different developmental toxicity profile in rabbits as compared with rats. In rats, the most sensitive endpoint of developmental toxicity was a syndrome of skeletal malformations including angulated or irregularly shaped clavicle, femur, fibula, humerus, ilium, radius, scapula, tibia, and/or ulna (Treinen et ai, 1995) . These types of skeletal abnormalities were not induced by this compound in the rabbit up to doses resulting in embryo/fetal toxicity. The NOAEL for MnDPDP for these abnormalities in the rat was 5 ^/mol/kg when administered intravenously daily on Days 6 through 17 of pregnancy. In rabbits, embryo/fetal toxicity, as evidenced by an increased postimplantation loss, was the most sensitive endpoint of developmental toxicity for MnDPDP. The NOAEL for MnDPDP for this endpoint was 40 ^mol/kg. As reviewed by Nau (1987) among others, species differences in teratogenic response are not at all uncommon and probably can be ascribed to intrinsic differences in tissue sensitivity or to pharmacokinetic phenomena resulting in differences, both quantitative and qualitative, in exposure of the embryo/fetus. In rats and dogs, the pharmacokinetics, biodistribution, and excretion of MnDPDP have been described (Grant et ai, 1994b) . This information, however, is not available for the rabbit.
In summary, the hepatobiliary magnetic resonance contrast agent mangafodipir trisodium was not teratogenic in the New Zealand White rabbit, but induced postimplantation loss when administered intravenously daily on Days 6 through 18 of pregnancy at a dose of 60 /^mol/kg/day (12-fold the proposed clinical dose of 5 ^mol/kg/day). These findings contrast with results in the Sprague-Dawley rat , in which mangafodipir trisodium was teratogenic when administered intravenously daily on Days 6 through 17 of pregnancy at a dose of 20 //mol/kg/day. Further experimentation on the mechanisms of these findings is necessary to make appropriate extrapolation of these results to humans.
